Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NABPLAGEMD in Metastatic Pancreatic Cancer
NCT03415854Phase 2Completed
- Sponsor
- HonorHealth Research Institute
- Start
- Jan 2018
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of paricalcitol in pancreatic ductal adenocarcinoma (PDAC), sponsored by HonorHealth Research Institute. Started Jan 2018; status: completed.
02
Drugs
paricalcitol
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03415854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415854.